Breast Cancer
5 years of tamoxifen improves 15-year survival by about a third in women with most common type of breast cancer
Published in Women's Health Weekly, August 18th, 2011
2011 AUG 18 -- In women with hormone-sensitive breast cancer (ie, oestrogen-receptor (ER) positive breast cancer), further benefits of adjuvant tamoxifen continue to accrue for at least 10 years after women stop taking the drug, according to an Article published Online First in The Lancet. The findings suggest that full compliance with 5 years of daily tamoxifen therapy would reduce the long-term chances of dying from breast cancer by at least a third.
Various treatments can be given after apparently successful breast cancer surgery to prevent any microscopic residual fragments eventually causing incurable breast cancer recurrence and death, and many...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Ovarian Cancer
Data from G. Ruggeri and Colleagues Advance Knowledge in Ovarian Cancer - Eclampsia
Data on Eclampsia Discussed by C. Cantubrito and Colleagues - Ovarian Cancer
Data on Ovarian Cancer Published by Researchers at University of Melbourne - Chlamydia
Findings from University of Florida in Chlamydia Reported - Ovarian Cancer
Investigators at CBRV Target Ovarian Cancer - Gynecology
Investigators at Massachusetts General Hospital Release New Data on Gynecology - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
